Coronavirus Update: AstraZeneca’s Vaccine Trials Cleared To Restart In the US, J&J Prepares To Restart Its Vaccine Study
Executive Summary
Two potential COVID-19 vaccine trials from AstraZeneca and Johnson & Johnson are set to resume in the US following temporary pauses due to safety concerns. Data from both could come later this year.
You may also be interested in...
Transparency On COVID Vaccine Clinical Holds Needed, Sharfstein Says; US FDA Advisory Cmtes Offer Venue
Former acting Commissioner Josh Sharfstein argues that while agency officials have done a commendable job in overall communication on COVID vaccine development, more information is needed on the clinical holds.
Real-World Data, AI Play Key Roles In COVID-19 Vaccine Programs
RWD has helped with development of multiple SARS-CoV-2 vaccines already and could be a useful tool for the future, as panelists discussed at the AI Cures conference.
Lack Of Details On J&J COVID Vaccine Trial Safety Pause Raises ACIP Concerns About Transparency
Patient confidentiality and trial blinding precluded a Janssen official from sharing specifics about the safety event that led to a study enrollment pause, but Advisory Committee on Immunization Practices representatives say the lack of detailed, publicly disclosed information is not helping vaccine confidence.